Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Trading Statement

10 Oct 2018 07:00

RNS Number : 4733D
Scapa Group PLC
10 October 2018
 

 

10 October 2018

LEI No. 213800QIPVTK5ES5UU36

 

Scapa Group plc ("Scapa" or "the Group")

 

 

Period end update

 

Scapa Group plc (AIM: SCPA) is today providing a period end update for the six months ended 30 September 2018.

Group trading profits* and margins are ahead of last year. Primarily due to the adverse currency movement against the equivalent period last year, revenue is down 3.4%.

Healthcare revenue grew 0.2% (3.4% on a constant currency basis). We anticipate the tech transfers and new programs will, as previously announced, start to benefit revenues during the second half of the year.

Industrial profit and margin improved on lower revenue, and we continue to make good progress toward the medium term margin target of 15%. The integration of Markel Industries is nearly complete and we expect the synergy benefit to come through during the second half of the year. We also announced the closure of our Liverpool facility in New York, USA.

Our cash generation remains strong and the Group ended the first six months with a net debt of £5.2m.

We remain confident of strong progress for the year and we anticipate the profit for the year will be in line with expectations, excluding the impact of the recently announced Gargrave healthcare transaction. Further details and the impact of this transaction will be included in the half year results which we expect to announce on 20 November 2018.

*Before exceptional items, amortisation of intangible assets and legacy pension costs and finance charges

Enquiries:

Scapa Group plc

Heejae Chae - Chief Executive

Oskar Zahn - Chief Financial Officer

 

0161 301 7430

 

Numis Securities Limited

(Nominated Adviser)

Mark Lander / Richard Thomas

 

 

 

020 7260 1000

 

Berenberg

(Joint Broker)

Chris Bowman

 

Weber Shandwick

Nick Oborne

 

 

 

020 3207 7800

 

 

020 7067 0721

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFKCDNPBDDCKK
Date   Source Headline
1st Mar 201710:22 amRNSAdditional Listing
23rd Feb 201711:03 amRNSHolding(s) in Company
16th Feb 20179:21 amRNSHolding(s) in Company
7th Feb 20174:16 pmRNSBlock listing Interim Review
3rd Feb 20173:53 pmRNSHolding(s) in Company
26th Jan 201710:10 amRNSDirector/PDMR Shareholding
25th Jan 20174:33 pmRNSBlock listing Interim Review
25th Jan 201711:49 amRNSHolding(s) in Company
23rd Jan 20179:18 amRNSDirector/PDMR Shareholding
9th Jan 20179:41 amRNSAdditional Listing
22nd Dec 20162:15 pmRNSAdditional Listing
15th Dec 20167:00 amRNSDirectorate Change
13th Dec 20161:29 pmRNSAdditional Listing
24th Nov 20164:30 pmRNSDirector/PDMR Shareholding
24th Nov 20164:20 pmRNSDirector/PDMR Shareholding
22nd Nov 20164:20 pmRNSAdditional Listing
22nd Nov 20167:00 amRNSHalf-year Report
12th Oct 20167:00 amRNSTrading Statement
27th Sep 20162:53 pmRNSDirector/PDMR Shareholding
21st Sep 20161:51 pmRNSAdditional Listing
6th Sep 201610:24 amRNSAdditional Listing
2nd Sep 201611:20 amRNSBlock listing Interim Review
31st Aug 20169:14 amRNSTotal Voting Rights
26th Aug 20167:00 amRNSDirector/PDMR Shareholding
12th Aug 201611:24 amRNSBlock listing Interim Review
11th Aug 20161:30 pmRNSDirector/PDMR Shareholding
10th Aug 201610:08 amRNSDirector/PDMR Shareholding
19th Jul 20164:58 pmRNSAdditional Listing
19th Jul 20167:00 amRNSAGM Statement
11th Jul 20163:48 pmRNSDirector/PDMR Shareholding
5th Jul 20162:25 pmRNSHolding(s) in Company
1st Jul 20162:58 pmRNSDirector/PDMR Shareholding
1st Jun 20163:49 pmRNSAdditional Listing
1st Jun 20167:00 amRNSAppointment of Joint Broker
24th May 20167:00 amRNSAcquisition
24th May 20167:00 amRNSFinal Results
18th May 201610:01 amRNSAdditional Listing
11th May 201610:45 amRNSHolding(s) in Company
18th Apr 20167:00 amRNSDirectorate Change
14th Apr 20167:00 amRNSTrading Statement
2nd Mar 20169:06 amRNSBlocklisting Interim Review
8th Feb 20169:49 amRNSBlocklisting Interim Review
28th Jan 20167:00 amRNSDirectorate Change
31st Dec 20157:00 amRNSTotal Voting Rights
15th Dec 20159:57 amRNSHolding(s) in Company
14th Dec 20158:26 amRNSHolding(s) in Company
14th Dec 20158:21 amRNSDirector/PDMR Shareholding
8th Dec 201511:46 amRNSHolding(s) in Company
8th Dec 201511:42 amRNSHolding(s) in Company
1st Dec 201510:52 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.